Considering that, our measured biomarkers (53BP1 foci, CA, MN and PFG) in lymphocytes represent only surrogate marker, leukemia risk should be associated with DNA damage and genomic instability in the hematopoietic stem cell. This evidence concerns the gene TP53BP1 and leukemia.